Furthermore, the patients with a high CD8 + mTILs/CD68 + TAMs ratio gained a major benefit from adjuvant trastuzumab, suggesting that the inflammatory conditions in the tumor microenvironment may influence the efficacy of trastuzumab, but further studies addressing this question are needed. Here, CD68 is linked to neoplasm.